NKGen Biotech, Inc. 8-K

What Happened

• NKGen Biotech, Inc. (NKGN) filed an 8-K reporting an amendment to a secured promissory note with AlpineBrook Capital GP I Limited. The Amendment was entered on January 12, 2026 and increases the Note’s principal to $26,135,106. The original Note was dated January 5, 2026.

Key Details

• Lender: AlpineBrook Capital GP I Limited.
• Additional funding: $295,000 (referred to as the “Second Additional New Loan”), increasing total principal to $26,135,106.
• Interest accrual: interest on $25,840,106 of principal accrues from January 5, 2026 (original Note date); interest on the $295,000 add-on accrues from January 12, 2026 (Amendment date).
• The obligation is under a secured promissory note (i.e., debt that is secured) and the company reported the amendment under Item 1.01 (material definitive agreement) and Item 2.03 (creation of a direct financial obligation) of the Form 8-K.

Why It Matters

• This filing confirms NKGen has taken on additional secured debt, increasing its outstanding loan balance. For investors, that means higher principal outstanding and potentially higher interest expense going forward; because the loan is secured, creditors may have claims on specified assets. The amendment’s timing and interest accrual dates clarify when the new funds began to incur interest, which affects short‑term cash needs and future expense recognition.